Tiotropium

Not Applicable

17/02/2025 Triple therapy inhalers for treating asthma or chronic obstructive pulmonary disease

The Ministry of Health’s Drug Advisory Committee has recommended:

• Fluticasone furoate/umeclidinium/vilanterol (Trelegy Ellipta) 100/62.5/25 mcg (30 inhalations) and 200/62.5/25 mcg (30 inhalations) inhalation powder for treating asthma; and

• Fluticasone furoate/umeclidinium/vilanterol (Trelegy Ellipta) 100/62.5/25 mcg (30 inhalations) inhalation powder for treating chronic obstructive pulmonary disease.

Funding status

[R] Fluticasone furoate/umeclidinium/vilanterol (Trelegy Ellipta) 100/62.5/25 mcg (30 inhalations) and 200/62.5/25 mcg (30 inhalations) inhalation powder are recommended for inclusion on the Standard Drug List (SDL) for the abovementioned indications from 1 April 2025.

[NR] SDL subsidy does not apply to any formulations or strengths of beclomethasone dipropionate/glycopyrronium/formoterol, budesonide/glycopyrronium/formoterol, mometasone furoate/glycopyrronium/indacaterol, or tiotropium.

02/07/2018 LAMA & LAMA/LABA for chronic obstructive pulmonary disease (COPD)

The Ministry of Health’s Drug Advisory Committee has recommended:

• Umeclidinium 62.5mcg inhalation powder for the:

  • Maintenance treatment of patients diagnosed by spirometry with chronic obstructive pulmonary disease (Group B or C) who have breathlessness.

• Umeclidinium/vilanterol 62.5/25mcg inhalation powder for the:

  • Maintenance treatment of patients diagnosed by spirometry with chronic obstructive pulmonary disease (Group B or C) who have frequent exacerbations (at least 2 per year or at least 1 leading to hospitalisation per year) and/or persistent breathlessness despite treatment with LAMA monotherapy.

  • Maintenance treatment of patients diagnosed by spirometry with chronic obstructive pulmonary disease (Group D) with persistent symptoms and frequent exacerbations.

Subsidy status

[R] Umeclidinium 62.5mcg inhalation powder and umeclidinium/vilanterol 62.5/25mcg inhalation powder are recommended for inclusion on the MOH Standard Drug List (SDL) for the abovementioned indications.

[NR] SDL subsidies do not apply to the following:

• Other LAMAs (glycopyrronium, tiotropium or aclidinium)

• Other LAMA/LABAs (indacaterol/glycopyrronium, tiotropium/olodaterol or aclidinium/formoterol)

Legend

This section displays recommendation from the MOH Drug Advisory Committee for subsidy and appropriate use of the drug as extracted from the Agency for Care Effectiveness (ACE) Drug Guidances. As this website is updated monthly, please refer to the ACE website for the most updated information.

Note:

General availability information reflected is based on the Public Healthcare Institutions’ (PHI) formulary on what is commonly used for treating their patient population and may or may not be available for patients not under the care of that institution. It does not reflect the PHI’s actual inventory availability and is subjected to change. Please consult the Public Hospitals or Polyclinics for details on availability and supply restrictions/considerations. General availability is not tied to any brand unless otherwise stated.

Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration